SCHEMBL12430694

SCHEMBL12430694

CCc1cccc(Nc2nc(Nc3cc(C4CC4)[nH]n3)c3ccccc3n2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 4/20 0.68
NTRK1 P04629 3/20 0.65
PDK1 Q15118 1/20 0.60
ULK2 Q8IYT8 1/20 0.60
NTRK3 Q16288 1/20 0.58
NTRK2 Q16620 1/20 0.58
GSK3B P49841 5/20 0.56
SRC P12931 4/20 0.56
AURKA O14965 1/20 0.56
PAK4 O96013 2/20 0.55
PAK1 Q13153 1/20 0.55
IGF1R P08069 3/20 0.54
AURKB Q96GD4 2/20 0.54
DYRK3 O43781 1/20 0.54
JAK2 O60674 1/20 0.54
PRKD3 O94806 1/20 0.54
MAP4K4 O95819 1/20 0.54
ABL1 P00519 1/20 0.54
LCK P06239 1/20 0.54
FYN P06241 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12430674 0.90 ULK1 (0.77) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL31471779 0.88 ULK1 (0.86) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL12430667 0.88 ULK1 (0.86) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL12430668 0.87 ULK1 (0.72) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL12430703 0.86 ULK1 (0.73) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL22072049 0.85 ULK1 (0.72) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL12430717 0.85 AURKA (0.78) NTRK1NTRK3NTRK2GSK3BSRC
SCHEMBL12430675 0.85 ULK1 (0.74) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL7108312 0.85 ULK1 (0.68) ULK1NTRK1PDK1ULK2NTRK3
SCHEMBL22034770 0.84 NTRK1 (0.88) ULK1NTRK1NTRK3NTRK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA ULK1 965/4885NTRK1 2111/4885PDK1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.